Ayub Adil, Rehmani Sadiq S, Al-Ayoubi Adnan M, Raad Wissam, Flores Raja M, Bhora Faiz Y
Department of Thoracic Surgery, Icahn School of Medicine, Mount Sinai Health System, New York, New York.
Department of Thoracic Surgery, Icahn School of Medicine, Mount Sinai Health System, New York, New York.
Ann Thorac Surg. 2017 Oct;104(4):1131-1137. doi: 10.1016/j.athoracsur.2017.04.043. Epub 2017 Jul 12.
Pulmonary resection for a second lung cancer after pneumonectomy is generally considered to be at prohibitive risk. Using a population-based database, we examined treatment patterns and survival in patients who underwent pulmonary resection after pneumonectomy for lung cancer.
We queried the Surveillance, Epidemiology, and End Results (SEER) database (1988-2012) to identify patients who underwent pneumonectomy and subsequently experienced contralateral non-small cell lung cancer (NSCLC). Multivariate logistic regression was performed to identify the factors associated with the receipt of surgical resection. Survival was estimated with the Kaplan-Meier method.
Of 13,370 patients who underwent pneumonectomy, 402 (3.0%) experienced subsequent contralateral NSCLC, and 170 (42%) met the selection criteria. Surgical resection was performed in 63 (37.1%) cases (sublobar n = 56, lobectomy, n = 7). Patients with stage I/II disease and tumor size 2 cm or smaller were more likely to undergo surgical procedures. The 1-month and 3-month mortality after resection was 11.1% (sublobar resection 10.7%, lobectomy 14.3%) and 12.7% (sublobar 12.5%, lobectomy 14.3%), respectively. The overall 1-year and 3-year survival after surgical resection was 79% and 54%, respectively. The patients who underwent sublobar resection had higher median overall survival than did those who underwent lobectomy (42 vs 18 months). Similarly, median survival after resection for metachronous tumors was higher than after resection for metastatic cancers (40 vs 28 months).
On the basis of our analysis of the SEER database, sublobar resection can be performed in selected patients with small tumors (≤2 cm) and early-stage disease (stage I/II). Although perioperative mortality is significant, the favorable 1-year and 3-year survival may justify the role of an additional procedure on the single lung.
肺叶切除术后再次行肺癌肺切除术的风险通常被认为过高。我们利用基于人群的数据库,研究了肺癌肺叶切除术后接受肺切除术患者的治疗模式和生存率。
我们查询了监测、流行病学和最终结果(SEER)数据库(1988 - 2012年),以确定接受肺叶切除术且随后发生对侧非小细胞肺癌(NSCLC)的患者。进行多因素逻辑回归分析以确定与接受手术切除相关的因素。采用Kaplan - Meier方法估计生存率。
在13370例接受肺叶切除术的患者中,402例(3.0%)随后发生对侧NSCLC,170例(42%)符合入选标准。63例(37.1%)患者接受了手术切除(亚肺叶切除56例,肺叶切除7例)。I/II期疾病且肿瘤大小为2 cm或更小的患者更有可能接受手术治疗。切除术后1个月和3个月的死亡率分别为11.1%(亚肺叶切除10.7%,肺叶切除14.3%)和12.7%(亚肺叶切除12.5%,肺叶切除14.3%)。手术切除后的总体1年和3年生存率分别为79%和54%。接受亚肺叶切除的患者的中位总生存期高于接受肺叶切除的患者(42个月对18个月)。同样,异时性肿瘤切除术后的中位生存期高于转移性癌切除术后的中位生存期(40个月对28个月)。
基于我们对SEER数据库的分析,对于选定的小肿瘤(≤2 cm)和早期疾病(I/II期)患者可进行亚肺叶切除。尽管围手术期死亡率较高,但良好的1年和3年生存率可能证明在单肺上进行额外手术的作用是合理的。